Showing 8141-8150 of 9130 results for "".
- Castle Biosciences Supports Patient-Focused Initiatives for Skin Cancer Awareness Monthhttps://practicaldermatology.com/news/castle-biosciences-supports-of-patient-focused-initiatives-for-skin-cancer-awareness-month/2461182/Castle Biosciences, Inc. will continue its ongoing collaboration with the Melanoma Research Foundation (MRF) and The Skin Cancer Foundation to support skin cancer research, education and advocacy, highlighting events during May, in recognition of Skin Cancer Awareness Month. “We a
- Cutera Hosts AviClear Webinar This Weekhttps://practicaldermatology.com/news/cutera-hosts-aviclear-webinar-this-week/2461178/Cutera hosts the first webinar for AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne, this week. Dermatologists Jeffrey S. Dover, MD, FRCPC and Julie C. Harper, MD will discuss the latest advancement in the treatment of acn
- Chicago Dermatological Society to Host Art of Skin Gala to Advance Diversity, Equity, and Inclusionhttps://practicaldermatology.com/news/chicago-dermatological-society-to-host-art-of-skin-gala-to-advance-diversity-equity-and-inclusion/2461176/The Chicago Dermatological Society (CDS) is launching the Art of Skin Gala, sponsored by Janssen Biotech, Inc. The event, to be held June 10, is described as a live, in color celebration of diversity, equity, and inclusion brought to life through the beauty of skin. The
- ePatch Using Electrical Field Stimulation Shows Promise for Wound Healinghttps://practicaldermatology.com/news/epatch-using-electrical-field-stimulation-shows-promise-for-wound-healing/2461175/A “smart” flexible electric patch (ePatch) developed by a collaborative team from the Terasaki Institute for Biomedical Innovation promises to address the challenges posed by existing electrical field (EF) stimulation devices for wound healing and offers many uniquely advantageous fea
- FDA Approves Sol-Gel Technologies' and Galderma's Epsolay for Rosaceahttps://practicaldermatology.com/news/fda-approves-sol-gel-technologies-and-galdermas-epsolay-for-rosacea/2461170/The FDA has approved Sol-Gel Technologies' Epsolay, a proprietary cream formulation of benzoyl peroxide, 5%, for the treatment of inflammatory lesions of rosacea in adults. The benzoyl peroxide in Epsolay is encapsulated within silica-based patented microcapsules. The silica-based s
- Study: Improved Survival Seen for DecisionDx-Melanoma Tested Patientshttps://practicaldermatology.com/news/study-improved-survival-seen-for-decisiondx-melanoma-tested-patients/2461168/Melanoma patients tested with DecisionDx-Melanoma plus traditional clinicopathologic factors showed improved survival compared to patients tested with only traditional clinicopathologic factors available to determine their treatment and follow-up plan, according to data presented the 18th Europea
- FDA Accepts Revance's BLA Resubmission for DaxibotulinumtoxinAhttps://practicaldermatology.com/news/fda-accepts-revances-bla-resubmission-for-daxibotulinumtoxina/2461167/The U.S. Food and Drug Administration (FDA) accepted Revance’s Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The FDA designated the BLA as a Class 2 resubmission, which has a six-mont
- Cutera to Celebrate AviClear Launch at ASLMShttps://practicaldermatology.com/news/cutera-to-celebrate-aviclear-launch-at-aslms/2461165/Cutera is celebrating the launch of AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne, during the ASLMS meeting in San Diego. ASLMS attendees are invited to the celebration for the launch of AviClear on Thursday, April 28,
- FDA Cracks Down on OTC HQ Productshttps://practicaldermatology.com/news/fda-cracks-down-on-otc-hq-products/2461164/The US Food and Drug Administration is cracking down on over-the-counter (OTC) skin lightening products containing hydroquinone (HQ) that do not meet the requirements to be legally sold as OTC drugs. The group issued warning letters to 12 companies explaining that all OTC skin lightenin
- Dr. Seemal R. Desai Elected to AAD Leadershiphttps://practicaldermatology.com/news/dr-seemal-r-desai-elected-to-aad-leadership/2461161/Seemal R. Desai, MD, FAAD, has been elected to serve as president of the American Academy of Dermatology (AAD) for one year beginning in March 2024. He will be installed as president-elect in March 2023. As president, Dr. Desai will lead the wor